Invasive aspergillosis is a life-threatening mold infection caused by Aspergillus species (most commonly A. fumigatus), primarily affecting immunocompromised hosts, with mortality exceeding 40–70% depending on the population and timeliness of treatment. [1-2] A high index of suspicion is essential, as clinical signs are nonspecific and delays in antifungal therapy are strongly associated with death. [3-4]
1. History
- Key HPI questions: Duration and character of fever (especially persistent fever refractory to broad-spectrum antibiotics in a neutropenic patient), cough (dry or productive), hemoptysis, pleuritic chest pain, dyspnea [5-6]
- Symptom characterization: Symptoms are often insidious and nonspecific; in profoundly neutropenic patients, persistent fever may be the only sign [6]
- Timing/triggers: Onset typically during periods of severe immunosuppression — post-chemotherapy nadir, early post-HSCT, during GVHD treatment, or during severe viral pneumonia (influenza, COVID-19) [7-8]
- Associated symptoms: Facial pain, nasal congestion, epistaxis (sinus disease); headache, seizures, focal neurologic deficits (CNS dissemination); skin lesions (cutaneous involvement) [6-7]
- Important negatives: Absence of response to broad-spectrum antibiotics, no improvement with empiric bacterial coverage, no alternative infectious etiology identified
2. Alarm Features
- Persistent fever >96 hours despite broad-spectrum antibiotics in a neutropenic patient [6]
- Hemoptysis — suggests angioinvasion and risk of massive hemorrhage [5-6]
- New focal neurologic deficits — CNS aspergillosis carries the highest mortality among all IA patterns [7-8]
- Pleuritic chest pain — indicates pulmonary infarction from vascular invasion [6]
- Rapidly progressive respiratory failure in an immunocompromised host
- Cacosmia (foul smell) — suggests necrosis of nasal/sinus tissue, requires urgent evaluation [7]
- Hemodynamic instability in a patient with known pulmonary aspergillosis — consider pericardial tamponade from direct extension [8-9]
3. Medications
First-line treatment (IDSA 2016 / ATS 2024 / NCCN)
- Voriconazole (Category 1): Loading dose 6 mg/kg IV q12h × 2 doses on Day 1, then maintenance 4 mg/kg IV q12h; oral step-down 200 mg q12h (≥40 kg) [8][10-11]
- Isavuconazole: Loading 200 mg q8h × 6 doses, then 200 mg daily — noninferior to voriconazole with fewer side effects and no QTc prolongation [7]
Alternative first-line
- Liposomal amphotericin B 3–5 mg/kg/day IV [8][12]
- Posaconazole: 300 mg BID Day 1, then 300 mg daily (noninferior to voriconazole in phase 3 trial) [7][11]
Salvage therapy
Combination therapy
Contraindicated/cautions
- Echinocandins should NOT be used as monotherapy for IA [7][12]
- Amphotericin B deoxycholate is avoided due to severe nephrotoxicity when lipid formulations are available [7]
- All mold-active azoles have significant CYP450-mediated drug interactions — review concurrent medications carefully (cyclosporine, tacrolimus, sirolimus, tyrosine kinase inhibitors, anticonvulsants, rifampin) [8][11]
- Voriconazole causes QTc prolongation; isavuconazole causes QTc shortening [7][11]
Therapeutic drug monitoring (TDM)
- Voriconazole: Trough at Day 5–7; target 1–5.5 μg/mL (>1 for efficacy, <5.5 to minimize CNS toxicity) [8][13]
- Posaconazole: Trough >1 μg/mL for treatment [12]
- Isavuconazole: TDM not routinely required [11][13]
The following table from the NCCN Guidelines on Prevention and Treatment of Cancer-Related Infections summarizes azole dosing and key considerations:
4. Diet
- No specific dietary triggers or restrictions for IA itself
- Neutropenic diet considerations are institution-dependent for at-risk patients (avoid raw/uncooked foods, unpasteurized products)
- Ensure adequate caloric and protein intake — malnutrition is a risk factor for poor outcomes
- Posaconazole oral suspension requires administration with a full meal or acidic carbonated beverage for adequate absorption; tablets and IV formulations are preferred [11]
- Hydration is important, particularly when using amphotericin B formulations (pre-hydration with normal saline to reduce nephrotoxicity)
5. Review of Systems
- Pulmonary: Cough, dyspnea, hemoptysis, pleuritic chest pain
- ENT/Sinus: Nasal congestion, facial pain/swelling, epistaxis, cacosmia, visual changes
- Neurologic: Headache, seizures, focal deficits, altered mental status (CNS dissemination)
- Dermatologic: New skin nodules or necrotic lesions (cutaneous aspergillosis or dissemination)
- Cardiac: Chest pain, dyspnea, signs of heart failure (endocarditis, pericarditis — rare) [8]
- Ophthalmologic: Visual changes (endophthalmitis from dissemination, or drug-related photopsia from voriconazole)
- Constitutional: Fever, night sweats, weight loss
6. Collateral History and Family History
- Transplant history: Type (allogeneic HSCT highest risk), conditioning regimen, GVHD status and treatment, time from transplant [8]
- Chemotherapy details: Agent, cycle, expected nadir timing, duration of neutropenia
- Immunosuppressive medications: Corticosteroid dose and duration, calcineurin inhibitors, anti-TNF agents, BTK inhibitors (ibrutinib) [7-8]
- Prior fungal infections or prophylaxis: Previous IA episodes, current antifungal prophylaxis (breakthrough IA occurs in ~44% of cases in some series) [14]
- Environmental exposures: Construction/renovation near hospital or home (airborne spore exposure)
- Family history: Chronic granulomatous disease (CGD) or other inherited immunodeficiencies [8]
7. Risk Factors
Classical (highest risk)
- Prolonged neutropenia (>10 days, ANC <500) [1][8]
- Allogeneic HSCT — especially with GVHD requiring immunosuppression [8]
- Hematologic malignancies — AML, MDS, relapsed/refractory leukemia [8]
- Solid organ transplant — lung transplant recipients at highest risk among SOT [8]
- High-dose or prolonged corticosteroids [7][15]
Non-classical (increasingly recognized)
- Severe viral pneumonia — influenza, COVID-19, RSV [7]
- ICU admission with structural lung disease, ARDS, mechanical ventilation [7][16]
- COPD (especially with corticosteroid use) [3][15]
- Decompensated liver cirrhosis [15-16]
- BTK inhibitors (ibrutinib) — associated with disseminated and CNS disease [7]
- Advanced AIDS (CD4 <100) [8]
- Chronic granulomatous disease [8]
- CMV co-infection in transplant recipients [8]
8. Differential Diagnosis
- Mucormycosis (zygomycosis): Similar risk factors and imaging; sinus involvement with black eschar is more classic; voriconazole is NOT active against Mucorales — critical distinction [7]
- Pneumocystis jirovecii pneumonia (PJP): Bilateral ground-glass opacities; typically in HIV/AIDS or prolonged steroid use; BDG positive but GM negative
- Bacterial pneumonia: More common; responds to antibiotics; less likely to show halo sign or nodules on CT
- Other invasive mold infections: Fusarium, Scedosporium — may have positive blood cultures (unlike Aspergillus); require different antifungal coverage
- Pulmonary tuberculosis: Cavitary disease, endemic exposure; AFB smear/culture distinguishes
- Nocardiosis: Nodular/cavitary lung disease in immunocompromised; modified acid-fast stain positive
- Lung malignancy/lymphoma: Mass lesions on CT; biopsy required for differentiation
- Pulmonary embolism with infarction: Pleuritic pain and hemoptysis; CT angiography distinguishes
9. Past Medical History
- Prior episodes of invasive fungal infection
- Hematologic malignancy type, status (remission vs. active/refractory)
- Transplant type and timeline
- Prior antifungal prophylaxis or treatment (azole exposure → resistance risk)
- Structural lung disease (COPD, bronchiectasis, prior TB cavities)
- Hepatic/renal dysfunction (affects drug selection and dosing)
- Cardiac history (QTc status — relevant for azole selection)
10. Physical Exam
Vital signs
- Fever (may be absent in profoundly immunosuppressed patients)
- Tachypnea, hypoxia (pulmonary involvement)
- Tachycardia, hypotension (sepsis, disseminated disease, pericardial tamponade)
Focused exam
- Lungs: Crackles, decreased breath sounds, pleural rub; often unremarkable early in disease
- Sinuses/Oropharynx: Nasal mucosal pallor or necrosis, septal perforation, palatal ischemia/eschar (also consider mucormycosis) [6]
- Skin: Papular or nodular lesions, necrotic eschars (disseminated disease) [7]
- Eyes: Fundoscopic exam for endophthalmitis (especially in disseminated disease)
- Neurologic: Focal deficits, cranial nerve palsies (CNS or orbital apex involvement) [6-7]
- Cardiac: Muffled heart sounds, JVD, pulsus paradoxus (pericardial tamponade) [8-9]
11. Lab Studies
Recommended labs
- Serum galactomannan (GM): OD index ≥0.5 is positive; sensitivity ~82%, specificity ~81% in hematologic malignancy/HCT populations; less sensitive in SOT and non-neutropenic patients [7][17]
- BAL galactomannan: Higher sensitivity (~85.5%) than serum GM; preferred diagnostic modality [18]
- 1,3-β-D-glucan (BDG): Positive >80 pg/mL; not specific for Aspergillus (also positive in Candida, PJP); sensitivity 55–96% [7]
- Aspergillus PCR (blood and/or BAL): Sensitivity ~85%, specificity ~76%; two positive tests increase specificity to 95% [7][19]
- CBC with differential: Assess neutrophil count and trend
- CMP: Hepatic and renal function (baseline before antifungal therapy and for monitoring)
- LFTs: Baseline and serial monitoring (azole hepatotoxicity)
- Procalcitonin, CRP: Nonspecific but may help differentiate bacterial vs. fungal etiology
- Voriconazole trough level: Day 5–7 after initiation; goal 1–5.5 μg/mL [8][13]
Expected abnormalities
- Elevated GM (serum and/or BAL), elevated BDG
- Leukopenia/neutropenia (underlying condition)
- Elevated inflammatory markers
False positives for GM: Piperacillin-tazobactam (historical, less with current assays), some cereals, cross-reactivity with other fungi [7]
The following table from the NEJM summarizes diagnostic testing modalities:
12. Imaging
First-line
- CT chest (non-contrast or with contrast):[7]
Key CT findings
- Halo sign: Nodule with surrounding ground-glass opacity — early finding, most common in neutropenic patients [7]
- Air crescent sign: Crescent of air within a cavitating nodule — later finding, often seen with neutrophil recovery [7]
- Nodules, consolidation, cavitation [20-21]
- Tree-in-bud pattern (airway-invasive disease) [18]
Additional imaging
- CT sinuses: If sinus symptoms or facial pain/swelling present
- MRI brain: If neurologic symptoms — assess for CNS aspergillosis (ring-enhancing lesions, abscesses) [6-7]
- Echocardiography: If concern for endocarditis or pericardial involvement [8]
- 18F-FDG PET/CT: May have a role in assessing extent of disease and treatment response [20]
When imaging may be normal
13. Special Tests
- Bronchoscopy with BAL: Essential for obtaining BAL GM, culture, PCR, and cytology (GMS stain, calcofluor white); BAL culture sensitivity 30–60% [3][20]
- Tissue biopsy: Gold standard for proven IA — demonstrates hyphal invasion of tissue; often precluded by thrombocytopenia or coagulopathy [3][7]
- Lateral flow assay (Aspergillus-specific): Point-of-care test detecting Aspergillus glycoprotein; rapid turnaround [20]
- EORTC/MSG criteria: Classification system for proven, probable, and possible IA — integrates host factors, clinical features, and mycological criteria [19]
- AspICU algorithm: For critically ill non-neutropenic patients — classifies colonization vs. putative IPA [16]
- Antifungal susceptibility testing: Important given rising azole resistance, especially in regions with environmental azole use [12]
14. ECG
- Baseline ECG is recommended before initiating azole therapy [11]
- Voriconazole and posaconazole: Associated with QTc prolongation — avoid in patients with baseline prolonged QTc or concurrent QTc-prolonging medications [7][11]
- Isavuconazole: Causes QTc shortening (clinical significance unclear); may be preferred in patients at risk for QTc prolongation [7]
- Aspergillus myocarditis (rare): May manifest as cardiac dysrhythmias, ST changes mimicking myocardial infarction [8]
- Pericarditis/tamponade: Low-voltage QRS, electrical alternans, diffuse ST elevation [9]
15. Assessment
Clinical summary
Invasive aspergillosis is a rapidly progressive, often fatal fungal infection requiring a high index of suspicion in at-risk populations. The lungs are the most commonly affected site, followed by the sinuses, with potential for hematogenous dissemination to the CNS, skin, heart, and other organs. [7]
Severity stratification
- Localized pulmonary disease — better prognosis with early treatment
- Disseminated disease (≥2 organs) — markedly worse outcomes
- CNS involvement — highest mortality among all IA patterns [8]
- Breakthrough IA (on prophylaxis) — may indicate resistant organism [14]
Mortality data
- Overall 1-year mortality: ~32% [2]
- Hematologic malignancy: attributable mortality 42% [1]
- HSCT recipients: attributable mortality up to 72% [1]
- ICU patients: mortality 55% [18]
- 90-day all-cause mortality in contemporary cohorts: ~46% [14]
- Untreated patients: median survival only 20 days vs. 130 days with voriconazole/posaconazole [4]
16. Treatment Plan
Initial stabilization
- ABCs, supplemental oxygen, hemodynamic support as needed
- Initiate antifungal therapy immediately upon clinical suspicion — do not wait for mycological confirmation [3][6]
- Reduce immunosuppression when feasible (decrease corticosteroids, hold immunosuppressive agents if possible) [7]
Primary antifungal therapy
- Voriconazole 6 mg/kg IV q12h × 2 doses → 4 mg/kg IV q12h (preferred first-line) [8][11]
- Isavuconazole 200 mg IV/PO q8h × 6 doses → 200 mg daily (alternative first-line, fewer side effects) [7]
- Liposomal amphotericin B 3–5 mg/kg/day IV (alternative if azole-resistant or contraindicated) [8][12]
Combination therapy
Duration
- Minimum 6–12 weeks; guided by clinical and radiographic response [12]
- Longer courses (months) often needed in persistently immunosuppressed patients
- Continue until resolution of immunosuppression and radiographic improvement [12]
Surgical intervention
Adjunctive measures
- Growth factor support (G-CSF/GM-CSF) to shorten neutropenia duration
- Granulocyte transfusions in refractory cases (limited evidence)
- Reversal of immunosuppression is the single most important adjunctive measure [7]
17. Disposition
Admission criteria (virtually all cases)
- All patients with suspected or confirmed invasive aspergillosis require inpatient admission [4][18]
- ICU admission for: respiratory failure, hemodynamic instability, massive hemoptysis, CNS involvement, pericardial tamponade
Observation indications
Specialist consultation triggers
- Infectious disease: All cases — for antifungal selection, TDM, and management guidance
- Pulmonology: Bronchoscopy with BAL for diagnosis
- Hematology/Oncology: Coordination of chemotherapy modifications and immunosuppression reduction
- Neurosurgery: CNS aspergillosis with mass effect
- Cardiothoracic surgery: Endocarditis, pericardial disease, massive hemoptysis
- Ophthalmology: Suspected endophthalmitis [8]
18. Follow Up / Return Precautions
Follow-up timing
- Serial serum GM levels (twice weekly during active treatment) to monitor response [7]
- Voriconazole trough levels at Day 5–7, then with dose changes or clinical deterioration [8][13]
- Repeat CT chest at 2–4 weeks to assess response (note: lesions may initially enlarge with neutrophil recovery before improving) [7][12]
- LFTs weekly during azole therapy
- Long-term follow-up with ID for duration of immunosuppression
Symptoms requiring immediate reassessment
- New or worsening hemoptysis
- New neurologic symptoms (headache, seizures, focal deficits)
- Worsening dyspnea or respiratory failure
- Visual changes (drug toxicity vs. endophthalmitis)
- New skin lesions (dissemination)
Patient counseling points
- Strict medication adherence — missed doses of azoles can lead to subtherapeutic levels and treatment failure
- Avoid grapefruit and other CYP3A4 inhibitors/inducers without consulting the care team
- Report visual disturbances (photopsia — common with voriconazole, usually transient) [7]
- Sun protection — voriconazole causes photosensitivity and long-term risk of cutaneous squamous cell carcinoma [7]
- Avoid driving at night initially (voriconazole-related visual disturbances)
Expected recovery course
- Clinical improvement typically within 1–2 weeks of appropriate therapy
- Radiographic improvement lags behind clinical response; CT lesions may paradoxically worsen with immune reconstitution [7]
- Treatment duration is prolonged (months); secondary prophylaxis may be needed if re-immunosuppression is anticipated
References
1. Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Official American Thoracic Society Clinical Practice Guideline. — Epelbaum O, Marinelli T, Haydour QS, et al. American Journal of Respiratory and Critical Care Medicine. 2024.
2. Invasive Pulmonary Aspergillosis Real-World Outcomes: Clinical Features and Risk Factors Associated With Increased Mortality. — Henao-Martínez AF, Corbisiero MF, Salter I, Chastain DB, Thompson GR. Medical Mycology. 2023.
3. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. — Hage CA, Carmona EM, Epelbaum O, et al. American Journal of Respiratory and Critical Care Medicine. 2019.
4. Evaluation of the Clinical Characteristics and Survival Outcomes of Invasive Pulmonary Aspergillosis Patients. — Feng Q, Ha X, Song Y. Frontiers in Microbiology. 2025.
5. Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment. — Heylen J, Vanbiervliet Y, Maertens J, Rijnders B, Wauters J. Seminars in Respiratory and Critical Care Medicine. 2024.
6. Aspergillosis. — Segal BH. The New England Journal of Medicine. 2009.
7. Aspergillus Infections. — Thompson GR, Young JH. The New England Journal of Medicine. 2021.
8. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. — Patterson TF, Thompson GR, Denning DW, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
9. Aspergillus Pericarditis: Clinical and Pathologic Features in the Immunocompromised Patient. — Walsh TJ, Bulkley BH. Cancer. 1982.
10. FDA Drug Label. — Updated date: 2025-09-26. Food and Drug Administration.
11. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.
12. Defining and Managing COVID-19-associated Pulmonary Aspergillosis: The 2020 ECMM/ISHAM Consensus Criteria for Research and Clinical Guidance. — Koehler P, Bassetti M, Chakrabarti A, et al. The Lancet. Infectious Diseases. 2021.
13. American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. — Dadwal SS, Hohl TM, Fisher CE, et al. Transplantation and Cellular Therapy. 2021.
14. Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients With Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era. — Lopez CM, Suarez JF, Mendoza MA, et al. Mycopathologia. 2026.
15. Galactomannan Detection in Broncho-Alveolar Lavage Fluid for Invasive Aspergillosis in Immunocompromised Patients. — de Heer K, Gerritsen MG, Visser CE, Leeflang MM. The Cochrane Database of Systematic Reviews. 2019.
16. Diagnosis and Treatment of Invasive Pulmonary Aspergillosis in Critically Ill Intensive Care Patients: Executive Summary of the German National Guideline (AWMF 113-005). — Wichmann D, Hoenigl M, Koehler P, et al. Infection. 2025.
17. Invasive Aspergillosis in Solid-Organ Transplant Recipients: Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice. — Husain S, Camargo JF. Clinical Transplantation. 2019.
18. Diagnosis, Clinical Features and Survival Analysis of Invasive Pulmonary Aspergillosis Among Critically Ill Patients: A Retrospective Cohort Study Based on Updated Criteria. — Gao L, Li S, Huang X, et al. Frontiers in Cellular and Infection Microbiology. 2025.
19. Polymerase Chain Reaction Blood Tests for the Diagnosis of Invasive Aspergillosis in Immunocompromised People. — Cruciani M, Mengoli C, Barnes R, et al. The Cochrane Database of Systematic Reviews. 2019.
20. Invasive Pulmonary Aspergillosis. — Ledoux MP, Guffroy B, Nivoix Y, Simand C, Herbrecht R. Seminars in Respiratory and Critical Care Medicine. 2020.
21. Epidemiological Characteristics of Patients With Invasive Pulmonary Aspergillosis Infected With Aspergillus Fumigatus From a Tertiary Hospital in Ningxia, China. — Kang Y, Li Q, Ma W, et al. Scientific Reports. 2025.